Post-marketing open-label observational clinical study of Vatantak Gold Tablet and Pain Kill Oil in painful inflammatory Musculoskeletal Conditions w.r.t Vatavyadhi

Med Pharma CRO0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年11月21日

试验速览

暂无简介。

•1.Patients 18 years or older, with musculoskeletal pain.
•2.Patients willing to give written informed consent.
•3.Patients are fit and no need for any hospital administration.
•4.Agree to following instruction of doâ??s and donâ??ts in regular daily lifestyle.
•5.Patients willing to perform all study related procedures including the use of study medicine, allow the physical and Biochemical tests and willing to document symptoms and medication.

•1.Use of steroids and/or recreational drugs in the past 6 months.
•2.Patients with open wounds or infection at the application site.
•3.Patients with renal impairment.
•4.Patients will be also excluded if they have poorly controlled diabetes mellitus.
•5.Female patients who are pregnant.
•6.Unstable medical or psychiatric illness.
•7.Chronic & acute disorders requiring hospital admission.
•8.Known HIV-positive, Hepatitis B or C status.
•9.Inability to carry out visits for the study.
•10.Inability to maintain current medication regimen.
•11.Inability or unwillingness to participate in all components of the study.

发起方

Med Pharma CRO